Table A1.
HR for PFS in a Cox Model
| Variable | PFS, Univariate |
PFS, Multivariate |
||
|---|---|---|---|---|
| HR | P | HR | P | |
| Total cohort, n = 206 | ||||
| Pathology, LC/A v classic or D/N | 3.13 | .0002 | 2.78 | .0013 |
| M stage, M+ v M0 | 2.22 | .0018 | 1.95 | .011 |
| β-catenin IHC, nucleonegative v nucleopositive | 3.12 | .014 | 3.01 | .034 |
| Patient cohorts with “low-risk” β-catenin nucleopositive tumors omitted (univariate, n = 181; multivariate, n = 164) | ||||
| Pathology, LC/A v classic or D/N | 2.78 | .0008 | 2.46 | .0069 |
| M stage, M+ v M0 | 1.96 | .0093 | 1.80 | .032 |
| MYC FISH, amplified v not amplified | 3.20 | .013 | 3.16 | .015 |
Abbreviations: HR, hazard ratio; PFS, progression-free survival; LC/A, large cell/anaplastic; D/N, desmoplastic/nodular; M, metastasis; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.